Eric Venker - Jul 20, 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
President & COO
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Stock symbol
ROIV
Transactions as of
Jul 20, 2023
Transactions value $
-$2,927,290
Form type
4
Date filed
7/24/2023, 09:31 PM
Previous filing
Jun 26, 2023
Next filing
Jul 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Options Exercise $614K +159K +24.74% $3.85 804K Jul 20, 2023 Direct
transaction ROIV Common Shares Sale -$1.8M -159K -19.83% $11.31 644K Jul 20, 2023 Direct F1, F2
transaction ROIV Common Shares Options Exercise $701K +182K +28.25% $3.85 826K Jul 21, 2023 Direct
transaction ROIV Common Shares Sale -$2.03M -182K -22.03% $11.13 644K Jul 21, 2023 Direct F1, F2
transaction ROIV Common Shares Options Exercise $127K +33.1K +5.14% $3.85 677K Jul 24, 2023 Direct
transaction ROIV Common Shares Sale -$362K -33.1K -4.88% $10.93 644K Jul 24, 2023 Direct F1, F2
transaction ROIV Common Shares Other -$179K -16.3K -2.53% $10.99 628K Jul 24, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -159K -1.04% $0.00 15.2M Jul 20, 2023 Common Shares 159K $3.85 Direct F4
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -182K -1.2% $0.00 15M Jul 21, 2023 Common Shares 182K $3.85 Direct F4
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -33.1K -0.22% $0.00 14.9M Jul 24, 2023 Common Shares 33.1K $3.85 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.
F2 The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. These sales was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.
F4 Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).